PPMI Completed & Ongoing Biologic Analyses

	Principal Investigator	Organization	Project Title	Data Availability	Analyte	Matrix	Included Enrollment Cohorts	Subcategories included	Visit(s)	Project ID	Notes
	Collaboration powered by Smartsheet   |   Report Abuse
1	Peggy Taylor, PhD	BioLegend	aSyn Measurements in Longitudinal CSF Samples From De Novo, PD, CT, SWEDD, Prodromal, & Genetic Cohorts​	Currently available	total aSyn, hemoglobin, & total protein	CSF	Healthy Control Parkinson Disease Prodromal SWEDD (legacy)	Genetic subjects	Baseline, 6, 12, 24, 36 months	102, 103, 111, 124	PD, HC, SWEDD through yr 3, prodromal & genetic through yr 1
2	Jessie Ni, PhD	BioLegend	Pilot and Large-Scale Study for ASYN in PPMI CSF	Bridging study available	total aSyn, hemoglobin, & total protein	CSF	Healthy Control Parkinson Disease		Bridging Study in 100 previously evaluated samples	201
3	Les Shaw, PhD	UPenn	A-beta 1-42, t-tau and p-tau 181 Measurements in PPMI CSF Samples using xMAP/Luminex Multiplex Immunoassay & Roche Elecsys	Currently available	Aβ, tau, & p-tau181 ​	CSF	Healthy Control Parkinson Disease Prodromal SWEDD (legacy)	Genetic subjects	Baseline, 6, 12, 24, 36 months	110, 125	Innogentics: PD, HC, & SWEDD through yr 1; Elecsys: PD, HC, & SWEDD through yr 3, prodromal & genetic through yr 1
4	Les Shaw, PhD	UPenn	PPMI CSF A-beta42, t-tau, and p-tau 181 Analysis 2019	Currently available	Aβ, tau, & p-tau181 ​	CSF	Healthy Control Parkinson Disease Prodromal SWEDD (legacy)	Genetic subjects	Baseline, 6, 12, 24, 36, 48, 60, 72, 84, 96, 108 months	159	75 Bridging study & 2,000+ remaining PPMI samples not yet analyzed from previous efforts
5	Clemens Scherzer, MD	Harvard	Evaluation of PD-linked Transcripts in PPMI	Currently available	aSyn transcripts	RNA from whole blood	Healthy Control Parkinson Disease		Baseline	105
6	Judith Potashkin, PhD	Rosalind & Franklin University	Whole Blood RNA Biomarkers of PD	Currently available	mRNA transcripts	RNA from whole blood	Healthy Control Parkinson Disease		Baseline	114
7	Martin Rabey, MD	BioShai Ltd.	Validation of a Blood-based Gene Expression Assay for Early Diagnosis & Monitoring Disease	Currently available	mRNA transcripts	RNA from whole blood	Healthy Control Parkinson Disease SWEDD (legacy)		Baseline, 12, 24, 36 months	119
8	Kendall Van Keuren-Jensen, PhD	TGen Foundation	RNAseq in PPMI	Currently available (summary files, raw data for cloud transfer, & data explorer)​	mRNA& miRNA sequencing​	RNA from whole blood	Healthy Control Parkinson Disease Prodromal SWEDD (legacy)	Genetic subjects	Baselilne, 6, 12, 24, 36 months	131, 133	Data available as summary files, raw data for cloud transfer, & data explorer
9	Matthew Farrer, PhD	University of BC	Clinical, Imaging, & Plasma & CSF Correlates of aSyn Genomic Variability	Currently available	SNCA genotyping​	DNA from whole blood	Healthy Control Parkinson Disease		Baseline	115
10	Travis Dunckley, PhD; Paula Desplats, PhD	Arizona State University; UCSD	Comprehensive Methylation Profiling of the PPMI Cohort​	Currently available	Methylation profiling​	DNA from whole blood	Healthy Control Parkinson Disease Prodromal	LRRK2 subjects	Baseline, 12, 24, 36 months	140
11	Sulev Koks, MD, PhD	Murdoch University	Association of Repetitive Elements with Parkinson's Disease Risk and Progression in the PPMI Cohort	Currently available	Tandem repeats	DNA	Healthy Control Parkinson Disease		Baseline	160
12	Kimberly Billingsley, PhD	NIH	Identifying the Role of Structural Variants in PD	Expected Q2 2023	Structural variants	DNA	Healthy Control Parkinson Disease		Various	179
13	Christos Proukakis, MD, PhD	University College London	Detection of GBA Mutations by Combination of Illumina & Nanopore Sequencing​	Currently available	Long read GBA sequencing	DNA	Parkinson Disease Prodromal	GBA subjects	Various	195
14	Dwight German, PhD	UT Southwestern	Blood biomarker for PD	Currently available	PD2 peptoid	Serum	Healthy Control Parkinson Disease		Baseline	123
15	Maria Teresa Pellecchia, PhD	University of Salerno	Insulin-like Growth Factor-1 as a Biomarker of Early Cognitive Impairment in PD	Currently available	IGF-1	Serum	Healthy Control Parkinson Disease		Baseline	113
16	Danielle Graham, PhD; Brit Mollenhauer, MD	Biogen; Paracelsus Elena Klinik	Investigation of Neurofilament Light Chain in Serum from the PPMI Cohorts as Progression Marker for PD​	Currently available	Neurofilament Light (NFL)​	Serum	Healthy Control Parkinson Disease Prodromal	Genetic subjects	PD & HC: Baseline, 6, 12, 24, 36, 60 months; Prodromal & genetic cohorts: Baseline, 6, 12, 24, 36 months	144
17	George Tofaris, MD, PhD	University of Oxford	Serum Neuronal Exosomes as Predictive or Dynamic Biomarkers in PD	Expected Q2 2023	Neuronal exosomes (aSyn)​	Serum	Parkinson Disease Prodromal	GBA & LRRK2 subjects	Baseline	204
18	Peter Lewitt, MD	Henry Ford Health System	Polyamine Biomarkers of Parkinson Disease Progression		Metabolomics	CSF Serum	Healthy Control Parkinson Disease		Baseline, 24 months	189
19	Alice Chen-Plotkin, MD, MSc	UPenn	Plasma Apolipoprotein A1 Level as a Biomarker in Parkinson’s Disease	Currently available	ApoA1 & EGF​	Plasma	Healthy Control Parkinson Disease		Baseline, 6, 12 months	112
20	Shawn Ritchie, PhD	Med-Life Discoveries	Validation of Plasmalogen Augmentation as a Viable Drug Target in PD​	Currently available	Plasmalogen​	Plasma	Healthy Control Parkinson Disease SWEDD (legacy)	Genetic subjects	Baseline	182
21	Pablo Sardi, PhD	Sanofi	GBA-Related Biomarkers in Parkinson's Disease	Currently available	GCase activity & sphingolipids​	CSF Plasma Whole blood	Healthy Control Parkinson Disease SWEDD (legacy)		Baseline, 12, 24, 36 months	132, 135
22	Jennifer Van Eyk, PhD	Cedars-Sinai	Post-Translational Modification & Protein Quantification of Plasma & CSF		Unbiased proteomics (DIA MS, AMP PD)	CSF Plasma	Healthy Control Parkinson Disease		Baseline & 3 longitudinal timepoints	177
23	Eline Appelmans, PhD	FNIH	Targeted Proteomics in AMP PD	Currently available	Targeted proteomics (O-Link Explore 1536, AMP PD)​	CSF Plasma	Healthy Control Parkinson Disease		Baseline & 3 longitudinal timepoints	196
24	Marion Buckwalter, PhD	Stanford	Adaptive Immune Markers for Predicting Cognitive Decline in PD	Currently available	Immune profiling	CSF Plasma	Healthy Control Parkinson Disease		Baseline, 48 months	181
25	Michael Schwarzschild, PhD	MGH & Denali	Metabolomic Analysis of Penetrance, Prognosis, & Tracking Biomarkers of LRRK2 PD	Plasma available; CSF Expected Q3 2023	Metabolomics	CSF Plasma	Healthy Control Parkinson Disease Prodromal	GBA & LRRK2 subjects	Plasma: Baseline,12, 24 months; CSF: Baseline only	180
26	Gavin Hudson, PhD	Newcastle University	The Role of Cell-Free Mitochondrial DNA in Neurodegenerative Disease	Currently available	Cell-free mitochondrial DNA	CSF	Healthy Control Parkinson Disease		Baseline, 36 months	130
27	Thomas Kremer, PhD; Kristen Taylor, PhD	Roche	CSF Neurotransmitter Metabolites as Promising Diagnostic & Disease Severity Biomarkers in Early-Stage PD Patients​	Currently available	Catecholamines​	CSF	Healthy Control Parkinson Disease		Baseline, 12, 24 months	122
28	Richard Batrla-Utermann, PhD	Roche	Roche NeuroTool Kit	Currently available	Roche Elecsys NeuroTool Kit (aSyn, GFAP, IL-6, S100b, neurogranin, NFL, sTREM2, YKL40)​	CSF	Healthy Control Parkinson Disease		Baseline, 6, 12, 24, 36, 48 months	152
29	Fiona Elwood, PhD	Novartis	Identification of Proteins & Protein Networks in Human CSF That Differentiate Within PD Patients​	Currently available	SomaLogic collaboration (with Merck & Novartis)​	CSF	Healthy Control Parkinson Disease Prodromal	Genetic subjects	Baseline	151
30	Liana Rosenthal, MD	John Hopkins	Is Poly ADP-ribose in the CSF a Biomarker for PD Diagnosis or Progression?​	Expected Q2 2023	Poly ADP-ribose​	CSF	Healthy Control Parkinson Disease		Baseline, 6, 12, 18, 24, 36,48, 60 months	165
31	Claudio Soto, PhD	Amprion	Monitoring the Progression & Pre-clinical Diagnosis of PD by Detection of aSyn Oligomers in CSF Using the PMCA Assay	Phase 1 Currently available; Phase 2 expected Q4	aSyn seeding (PMCA)- Round Robin & Phase 2​	CSF	Healthy Control Parkinson Disease Prodromal SWEDD (legacy)	Genetic subjects	Phase 1: BL, 36, mo; Phase 2: PD, HC, SWEDD at BL, prodromals at all visits, SNCA at all visits, LRRK2/GBA PD at BL and NMC at BL & all visits for phenoconverted	155	Phase 1 (Baseline & 36 months) PD, CT, SWEDD currently available; remaining data expected EOY
32	Roland Heym, PhD	Abbvie	Evaluation of Seeding-competent aSyn in the CSF as a Biomarker for Parkinson’s Disease	Currently available	aSyn seeding​ (RT-QuIC)- Round Robin	CSF	Healthy Control Parkinson Disease SWEDD (legacy)		Baseline, 36 months	173
33	Byron Caughey, PhD	NIH	aSyn Seeding Assay Round Robin- NIH​	Currently available	aSyn seeding​ (RT-QuIC)- Round Robin	CSF	Healthy Control Parkinson Disease SWEDD (legacy)		Baseline, 36 months	172
34	Kirsten Taylor, PhD	Roche	aSyn PMCA Assay at Amprion	Currently available	aSyn seeding​ (PMCA in leftover samples)	CSF	Healthy Control Parkinson Disease		Baseline, 12, 24 months	176
35	Kalpana Merchant, PhD	TransThera	Do Urinary BMP Levels Change with Disease Progression in Idiopathic & Genetic PD?	Currently available	BMP	Urine	Healthy Control Parkinson Disease Prodromal	GBA & LRRK2 subjects	PD, HC, & GBA: Baseline only; LRRK2: Baseline, 12, 24 months	145
36	Sebastian Virreira Winter, PhD	OmicEra​	Targeted & Untargeted MS Based Proteomics of Urine in PD	Currently available	Urine proteomics	Urine	Healthy Control Parkinson Disease Prodromal	GBA & LRRK2 subjects	PD, HC, & GBA: Baseline only; LRRK2: Baseline, 12, 24 months	190
37	Eleanor Coffey, PhD	Turku Centre for Biotechnology​	PD Signature Validation Project Related to "Improving Patient Diagnosis, Stratification & Disease Monitoring in PD"		Protein handling	PBMCs	Healthy Control Parkinson Disease Prodromal	Genetic subjects	3 longitudinal timepoints	170
38	Diana Matheoud, PhD	Université de Montréal	Mitochondria Autoreactivity in PD Patients as a New Biomarker for the Disease	Sample shipment pending	Mitochondrial autoreactivity​	PBMCs	Healthy Control Parkinson Disease		54, 96 months	178
39	Satpal Virdee, PhD,	University of Dundee​	Profiling PINK1-Parkin Functionality in Patient Fibroblasts Using Chemical Probes	Currently available	PINK1	Fibroblasts	Healthy Control Parkinson Disease		n/a	127
40	Marlene Jacobson, PhD	University of Dundee​	Investigating the Effect of Small Molecules to Rescue Lysosomal & GBA-1 Deficiencies in GBA-PD	Currently available	Lysosomal rescue​	Fibroblasts	Healthy Control Parkinson Disease		n/a	158
41	Alejandro Pezzulo, MD	University of Iowa	Multidisciplinary Analysis of Metabolic Dysregulation in Parkinson's Disease	Expected Q1 2023	Metabolic profiling	Fibroblasts	Healthy Control Parkinson Disease		n/a	194
42	Xinnan Wang, PhD	Stanford University​	Miro, a Biomarker for Parkinson’s Disease	Currently available	Miro	Fibroblasts iPSCs	Healthy Control Parkinson Disease Prodromal	Genetic subjects	n/a	129
43	Lalitha Madhavan, PhD	University of Arizona​	Development of a Biomarker Platform for Parkinson’s disease Using Patient-derived Cells		Cellular phenotype biomarkers	Fibroblasts iPSCs	Healthy Control Parkinson Disease		n/a	175
44	Nilima Prakash, PhD	Hamm-Lippstadt University of Applied Sciences​	Altered Calcium Activity Patterns in Developing Dopaminergic Neurons from PD Patients as an Early Indicator of Disease Predisposition or Progression	Expected Q2 2023	Calcium activity	Fibroblasts iPSCs	Healthy Control Parkinson Disease		n/a	136
45	Rachit Bakshi, PhD	MGH/MIND​	Urate & Nrf2 Pathway Effects on Mutant LRRK2 Toxicity in iPSC-Derived DA Neurons	Currently available	Urate & Nrf2​	iPSCs	Healthy Control Parkinson Disease Prodromal	LRRK2 subjects	n/a	137
46	Andy Singleton, PhD	NIA	The Foundational Data Initiative	Currently available; interactive portal currently under development, expected Q3 2021	Transcriptional activity, gene regulation, epigenetics​	iPSCs	Healthy Control Parkinson Disease Prodromal SWEDD (legacy)	Genetic subjects	n/a	150	Data portal under development
47	Mark Cookson, PhD​	NIA	LRRK2 Genetic Risk Variants in PD	Expected Q3 2023	LRRK2 functional variants​	iPSCs	Healthy Control Parkinson Disease Prodromal	Genetic subjects	n/a	139
48	Nic Dzamko, PhD	University of Sydney​	Inflammatory phenotypes in differentiated human LRRK2 & GBA mutation IPS cell lines	Currently available	Inflammation/​lysosomal function	iPSCs	Healthy Control Parkinson Disease Prodromal	GBA & LRRK2 subjects	n/a	141
49	Aaron Day Williams	Flagship 60​	Investigation of Phenotypic Differences Between Familial PD, Idiopathic PD and Controls in Patient-derived iPSCs	Currently available	Phenotyping	iPSCs	Healthy Control Parkinson Disease Prodromal	LRRK2 subjects	n/a	156
50	Matt LaVoie, PhD	Brigham & Women’s, Harvard​	Role of LRRK2 in Gcase-mediated Alterations in Lysosome Functions & aSyn Metabolism	Expected Q2 2023	LRRK2 at lysosomes	iPSCs	Parkinson Disease	GBA subjects	n/a	149
51	Dimitri Krainc, MD	Northwestern University	Convergence of LRRK2 & GBA1 in the Pathogenesis of Parkinson’s Disease	Expected Q1 2023	GCase activity in dopaminergic neurons​	iPSCs	Healthy Control Parkinson Disease	LRRK2 subjects	n/a	148
52	Dong-Gyu Jo, PhD	Sungkyunkwan University​	Study for the Propagation of aSyn (Screening the Propagation Relative Genes)	Expected Q1 2023	aSyn propagation	iPSCs	Healthy Control Parkinson Disease	GBA & LRRK2 subjects	n/a	174
53	Ellen Sidransky, MD​	NIH	Development of Novel TRPML1 Activator for Treatment of PD		Calcium channel agonists	iPSCs	Healthy Control Parkinson Disease		n/a	154
54	Magdalene Moran, PhD	Caraway Therapeutics​	Developing TMEM175 Activators as Therapeutics for PD	Expected Q2 2023	TMEM175 activators​	iPSCs	Parkinson Disease	GBA subjects	n/a	199
55	Maximiliano Gutierrez, PhD	Francis Crick Institute​	The Role of LRRK2 Kinase Activity in Human Macrophage Function	Expected Q1 2023	LRRK2 kinase activity	iPSCs	Parkinson Disease	LRRK2 subjects	n/a	161
56	Antony Cooper, PhD	Garvan Institute​	Phenotypic Confirmation of a Potential New Genetic Subtype of Parkinson’s Disease	Expected Q1 2023	Genetic subtyping	iPSCs	Healthy Control Parkinson Disease		n/a	188
57	Robert Krencik, PhD	Houston Methodist Research Institute​	Midbrain Asteroids to Interrogate Human Astrocyte Function within Neural Networks		Intracellular comms & astrocyte reactivity​	iPSCs	Healthy Control Parkinson Disease	GBA subjects	n/a	168
58	Claudio Soto, PhD	University of Texas​	A Novel Model of Parkinson’s Disease in Lab-generated Mini-brains	Expected Q1 2023	Characterization of midbrain organoids​	iPSCs	Healthy Control Parkinson Disease	LRRK2 & SNCA subjects	n/a	166
59	Erika Holzbaur, PhD	UPenn​	Investigating Mitochondrial Trafficking Deficits Across PD Models	Expected Q2 2023	Mitochondrial trafficking​	iPSCs	Healthy Control	Genetic subjects	n/a	198
60	Thomas Schwarz, PhD	Boston Children’s Hospital​	Mitochondrial Transport Defects as a Potential Biomarker in Patient-derived Cells	10HC, 3 SNCA, 1 LRRK2, 2 PD lines available; Remaining expected Q1 2023​	Mitochondrial transport​	iPSCs	Healthy Control Parkinson Disease	Genetic subjects	n/a	153
61	Emmanouil Metzakopian, PhD	University of Cambridge ​	High-throughput Single Cell Unbiased Lipidomics Assay in Human iPSC-derived​	Expected Q3 2023	Lipidomics​	iPSCs	Healthy Control Parkinson Disease Prodromal	Genetic subjects	n/a	183
62	Deniz Kirik, MD, PhD	University of Sydney​	Circuitry and Brain-body Interactions	Expected Q1 2024	Circuitry*​	iPSCs	Parkinson Disease Prodromal	LRRK2 & SNCA subjects	n/a	193
63	Xiqun Chen, MD, PhD	Mass General Hospital​	From Cancer Associations to Altered Immunity in the Pathogenesis of Parkinson’s Disease	Expected Q2 2024	Inflammation*	iPSCs	Healthy Control Parkinson Disease	LRRK2 subjects	n/a	197
64	Daphne Koller, PhD​	Insitro	Insitro PPMI Cell Line Application	Expected Q2 2023	2D dopaminergic neuronal culture phenotyping​	iPSCs	Healthy Control Parkinson Disease	GBA & LRRK2 subjects	n/a	187
65	Manoj Pandey, PhD	Cincinnati Children’s Hospital​	Setting up the Translational Value of Complement 5a Induction of Brain Inflammation & Neuronal Loss in Human Patients w/ Parkinson’s Disease	Expected Q2 2023	Neuroinflammation	iPSCs	Healthy Control Parkinson Disease	GBA subjects	n/a	167
66	Kiroaki Kaku, PhD	Western Michigan University​	The Role of FAIM in Parkinson’s Disease​	Expected Q3 2023	FAIM	iPSCs	Parkinson Disease	GBA & SNCA subjects	n/a	206
67	Adam Mamais, PhD	University of Florida​	Converging Pathways of LRRK2 & PINK1 Biology Impacting Iron Homeostasis & Mitochondrial Function	Expected Q2 2023	Iron & mitochondrial homeostasis​	iPSCs	Healthy Control Parkinson Disease	LRRK2 subjects	n/a	202
68	Andrew Singleton, PhD	NIA	Selected Genetic Variants Genotyped Using NeuroX Array	Currently available	NeuroX genotyping	DNA from whole blood	Healthy Control Parkinson Disease Prodromal SWEDD (legacy)	Genetic subjects	Baseline	106/107
69	Andrew Singleton, PhD	NIA	GBA Sequencing	Currently available	GBA sequencing	DNA from whole blood	Healthy Control Parkinson Disease SWEDD (legacy)		Baseline	126
70	Andrew Singleton, PhD	NIA	Immunochip Genotyping on DNA Samples from PPMI	Currently available	Immunochip genotyping​	DNA from whole blood	Healthy Control Parkinson Disease SWEDD (legacy)		Baseline	108
71	Andrew Singleton, PhD	NIA	Exome Sequencing of PPMI samples	Currently available	Whole exome sequencing	DNA from whole blood	Healthy Control Parkinson Disease SWEDD (legacy)		Baseline	116
72	Andrew Singleton, PhD	NIA	Whole Genome Sequencing & Analysis of PPMI Prodromal & Genetic Cohorts & Genetic Registry​	Currently available	Whole genome sequencing	DNA from whole blood	Healthy Control Parkinson Disease Prodromal SWEDD (legacy)	Genetic subjects	Baseline	118
73	Andrew Singleton, PhD	NIA	APOE4 Genotyping​	Currently available	APOE4 genotyping​	DNA from whole blood	Healthy Control Parkinson Disease SWEDD (legacy)		Baseline	104
74	Dena Hernandez, PhD	NIA​	DNA Methylation in PPMI	Currently available	DNA methylation	DNA from whole blood	Healthy Control Parkinson Disease SWEDD (legacy)		Baseline	120
75	Cornelis Blauwendraat, PhD	NIA	Long read DNA sequencing of the PPMI cohort​	Expected Q3 2023	Long read DNA sequencing​	DNA from whole blood	Healthy Control Parkinson Disease Prodromal SWEDD (legacy)	Genetic subjects	Baseline	171
76	Rebecca Selzer, PhD	FUJIFILM Cellular Dynamics, Inc.	Production and Commercialization of Differentiated Cell Types	Expected Q3 2023	Dopaminergic neurons	iPSCs	Healthy Control Parkinson Disease Prodromal SWEDD (legacy)	Genetic subjects	n/a	218	Differentiation into commercially available dopaminergic neurons
77	Anumantha Kanthasamy, PhD	Iowa State University	PPMI a-Syn Skin Seeding Assay	Expected Q3 2023	aSyn seeding​ (RT-QuIC)- Round Robin	Skin	Healthy Control Parkinson Disease		Baseline	211
78	Karen MacLeod, Claudio Soto, PhD	Amprion	Development and Optimization of Semi-Quantitate PMCA for Analysis of Soluble ASYN Aggregates in CSF in Amprion's Clinical Laboratory	Currently available	aSyn seeding (PMCA)	CSF	Healthy Control Parkinson Disease		Various	207	Used warmed CSF from various visits
79	Khalil Ramadi	New York University	Neural Chemical Delivery System for Treatment of Parkinson's Disease	Expected Q3 2024		Fibroblasts iPSCs	Healthy Control Parkinson Disease		n/a	216
80	Deniz Kirik	University of Sydney	An in vivo approach to elucidate the pathobiology of PD-associated genes using human diseased neurons	Expected Q4 2023		Fibroblasts iPSCs	Healthy Control Parkinson Disease		n/a	193
81	Anthony Schapira	UCL Medical School	The genome-microbiome axis in the cause of Parkinson disease: Mechanistic insights and therapeutic implications from experimental models and a genetically stratified patient population.	Expected Q1 2024		iPSCs	Healthy Control Parkinson Disease		n/a	223
82	Bahareh Ajami, Dario Alessi	Oregon Health & Science University, University of Dundee	Investigating the influence of genetic risk factors of PD on peripheral immune cells to identify potential biomarkers for prediction of conversion of non-manifesting to manifesting carriers.	Expected Q3 2023		PBMCs Plasma	Parkinson Disease		n/a	213, 213
83	Céline Galvagnion	University of Copenhagen	Understanding selective neuronal vulnerability in the context of Parkinson's Disease	Expected Q1 2024		iPSCs				224
84	Julian Peter Sefrin	Abbvie	Evaluation of TMPRSS5 (Spinesin) in the CSF as a potential biomarker for early Parkinson’s disease diagnosis and progression	Currently available		CSF				219
85	Massimiliano Bianchi	Ulysses Neuroscience Ltd	Validation of microtubule dynamics as a novel target in Parkinson’s disease	Expected Q2 2023		iPSCs			n/a	203
86	Omar Mabrouk	Biogen	CSF total LRRK2 measurements as a Biomarker in genetic PD	Expected Q1 2023		CSF				221
87	Zinnhardt	Roche	Identification of NLRP3 Inflammasome-related biomarkers in PPMI CSF Samples	Currently available		CSF				209
88	Susanna Narkilahti	University of Tampere	Electrophysiological Phenotype Characterization of iPSC-derived Neuronal Cells with PD-linked LRRK2 Mutations during Network Formation and Alpha-Synuclein Seeded Aggregation	Expected Q2 2024		iPSCs			n/a	227
89	Sonia Gandhi	University College London	Defining mechanisms in neurons and oligodendrocytes that drive progression in Parkinson’s	Expected Q4 2024		iPSCs			n/a	229
90	Rhalena Thomas	McGill University	A pipeline for massive multiplexing of iPSC-derived dopaminergic neurons and microglia for cohort-scale transcriptomics in PD	Expected Q4 2024		iPSCs			n/a	230
91	Lezanne Ooi	University of Wollongong	Metabolic phenotyping in PD dopaminergic neurons and neuronal-glial co-cultures using high-throughput single-cell metabolomics and lipidomics	Expected Q2 2024		iPSCs			n/a	231
92	Gist Croft	The New York Stem Cell Foundation	A cohort-wide resource of transcriptomic and morphological phenotypes in defined neural cell types	Expected Q2 2024		iPSCs			n/a	232
93	Laurent Roybon	Lund University	Uncovering proteomic alterations in Parkinson’s disease using patient-specific iPSC-derived brain cells	Expected Q2 2024		iPSCs			n/a	233
94	Laurent Roybon	VARI	Omic-based analyses of PD iPSC-derived brain cells	Expected Q3 2024		iPSCs			n/a	234
95	Lalitha Madhavan	University of Arizona	Deep phenotyping of PD relevant mitochondrial and autophagic mechanisms in human iPSC-derived neural cells	Expected Q4 2024		iPSCs			n/a	235
96	Souvik Modi	ESYA Labs	ESYA PD360: A multi-parametric platform for establishing a novel lysosome-based biomarker and identifying therapeutic interventions for Parkinson’s Disease	Expected Q1 2024		Fibroblasts			n/a	236
97	Daniel Ysselstein	Vanqua Bio	Glucocerebrosidase Activation as a Therapeutic Strategy for Parkinson’s Disease	Expected Q1 2024		iPSCs			n/a	239
98	Hilde Nilsen	Oslo University Hospital	Mitochondrial Transcription regulation via Base Excision Repair	Expected Q1 2024		iPSCs			n/a	241
99	Luis Concha	Amprion	Evaluation of αSyn seed levels in prodromal cases by means of a semi-quantitative seed amplification assay & Validation of Clinical Accuracy of the Rapid Qualitative αSynuclein Seed Amplification Assay in the Amprion Clinical Laboratory	Expected Q1 2024		CSF				242